title: Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
authors.forename: Donatella
authors.initials: D
authors.lastname: Pistolesi
authors.forename: Gianluca
authors.initials: G
authors.lastname: Giannarini
authors.forename: Giulia
authors.initials: G
authors.lastname: Stampacchia
authors.forename: Cesare
authors.initials: C
authors.lastname: Selli
mesh_terms: D000328:Adult; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D028761:Withholding Treatment; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A